Homeopathic Nasal Spray Firm Warned About Microbial Contamination Needs GMP Remediation

FDA advises additional recalls of Green Pharmaceuticals’ SnoreStop NasoSpray could be needed. Agency’s testing showed a batch of SnoreStop NasoSpray is adulterated because “it consists in whole or in part of any filthy, putrid, or decomposed substance.”

Shutterstock

The first US homeopathic firm to receive a warning since the Food and Drug Administration published a final guidance on regulating Rx and OTC products in the category likely would have attracted the agency’s scrutiny independent of the guidance.

The FDA Office of Regulatory Affairs’ Division of Pharmaceutical Quality Operations IV advised Green Pharmaceuticals Inc

The agency said its testing of a batch of SnoreStop NasoSpray showed the product is adulterated under FDA regulations because “it consists in whole or in

More from Compliance

Over The Counter: Why OTC Firms Should Care About Rx Advertising, With AdverCheck’s James Walmsley

 
• By 

HBW Insight speaks to AdverCheck managing director James Walmsley about the rise of direct-to-consumer prescription drugs marketing in the UK, and its impact on the consumer healthcare industry.

ASA Files: ACME Vapes Case Shows Marketers Must ‘Know Their Audience’

 
• By 

A recent ASA case involving an ad for vape products shows that marketers shouldn’t assume that professional online networks like LinkedIn are any different to other social media platforms when it comes to UK advertising codes.

US Proposal To Remove Phenylephrine From OTC Monograph Could Stress-Test Streamlined Process

 

Proposed administrative order likely is first to prompt opposition from OTC industry or other stakeholders potentially delaying or deferring the agency’s expectation for moving its proposal to a deemed final order effective one year after it would be published.

Perrigo’s Formula To Drive Earnings Rebound Swings On Further Formula Business Recovery

 

“The infant formula business is recovering and we've taken actions to simplify and consumerize our business, but there's a lot more work to do,” says CEO Patrick Lockwood-Taylor as Perrigo’s announced latest results.

More from Policy & Regulation

US Tariffs Pose ‘Existential Threat’ To EU Medical Devices Industry

 
• By 

AESGP, MedTech Europe and other associations representing medtech companies including manufacturers of self-care devices call for such products to be included in European Commission proposals for “zero-for-zero” trade in industrial goods between Europe and the US.

Stakeholders Hope US FDA’s Proposed Animal Test Phase-Out For Drugs Will Extend To OTCs, Cosmetics

 
• By 

The US Food and Drug Administration has released a roadmap to adopt new approach methodologies in lieu of animal testing for monoclonal antibody therapies and other drugs, which may include OTC drugs though the proposal does not specifically include cosmetics.

Melatonin And Buccal Acyclovir On German Switch Committee Agenda

 
• By 

An application for melatonin as an OTC medicine is on the agenda for the next German switch committee meeting, despite the hormone being widely available in food supplements. Acyclovir as a buccal tablet and second-generation antihistamine rupatadine are also up for discussion.